Table 3. Adverse Eventsa.
| Event | No. (%) | P value | |
|---|---|---|---|
| Plasma (n = 49) | PCC (n = 51) | ||
| Transfusion reactionb | 1 (2.0) | 0 | .49 |
| DVT | 0 | 1 (2.0) | >.99 |
| Mesenteric ischemia | 3 (6.1) | 1 (2.0) | .36 |
| Stroke/TIA | 1 (2.0) | 2 (3.9) | >.99 |
| STEMI | 1 (2.0) | 0 | .49 |
| Thromboembolic eventc | 2 (4.1) | 1 (2.0) | .61 |
| Acute kidney injury | 18 (36.7) | 21 (41.2) | .69 |
| Kidney failure with new KRT | 4 (8.2) | 5 (9.8) | >.99 |
| ARDS | 4 (8.2) | 4 (7.8) | >.99 |
| Reoperation for bleeding within 48 h | 5 (10.2) | 3 (5.9) | .48 |
| Death within 30 d | 2 (4.1) | 1 (2.0) | .61 |
Abbreviations: ARDS, acute respiratory distress syndrome; DVT, deep vein thrombosis; KRT, kidney replacement therapy; PCC, prothrombin complex concentrate; STEMI, ST-segment elevation myocardial infarction; TIA, transient ischemic attack.
a
Adverse events are summarized using No. (%) and compared between groups using the Fisher exact test.
b
Transfusion reaction denotes transfusion-related acute lung injury, hemolytic transfusion reaction, or anaphylactic or allergic transfusion reaction.
c
Thromboembolic event was any DVT, mesenteric ischemia, stroke or TIA, or STEMI verified as thromboembolic in nature.